Skip to Main Content

Advertisement

Skip Nav Destination

Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies

Mol Cancer Ther (2015) 14 (12_Supplement_2): C86.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Ye Feng
  • Haider Mahdi
  • Richard Piekarz
  • Jan H Beumer
  • Timothy W Synold
Bioanalysis (2024) 16 (8): 227.
  • Yangfeng Li
  • Zhengnan Shen
  • Kiira Ratia
  • Jiong Zhao
  • Fei Huang
  • Oleksii Dubrovyskyii
  • Divakar Indukuri
  • Jiqiang Fu
  • Omar Lozano Ramos
  • Gregory R. J. Thatcher
  • Rui Xiong
Journal of Medicinal Chemistry (2024) 67 (4): 2712.
  • Jiawei Guo
  • Qingquan Zheng
  • Yong Peng
Pharmacology & Therapeutics (2023) 243: 108354.
  • Filipa Moreira-Silva
  • Rui Henrique
  • Carmen Jerónimo
Frontiers in Oncology (2022) 12
  • Yangfeng Li
  • Jiong Zhao
  • Lauren M. Gutgesell
  • Zhengnan Shen
  • Kiira Ratia
  • Katherine Dye
  • Oleksii Dubrovskyi
  • Huiping Zhao
  • Fei Huang
  • Debra A. Tonetti
  • Gregory R. J. Thatcher
  • Rui Xiong
Journal of Medicinal Chemistry (2020) 63 (13): 7186.
  • Zhiqing Liu
  • Pingyuan Wang
  • Haiying Chen
  • Eric A. Wold
  • Bing Tian
  • Allan R. Brasier
  • Jia Zhou
Journal of Medicinal Chemistry (2017) 60 (11): 4533.
Close Modal

or Create an Account

Close Modal
Close Modal